GlassScriptPhysician profile
Christopher Sr Dakhil
NPI 1972721348
$59,078.58
in general payments reported to CMS, 2019-2025
94 companies · $4,078 in 2025
The $4,078 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $6,187 · 2020: $6,169 · 2021: $6,405 · 2022: $13K · 2023: $18K · 2024: $4,814 · 2025: $4,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $8,391 · Travel and Lodging: $1,478 · Honoraria: $1,200 · Education: $198 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,808.75 |
| Food and Beverage | $8,391.24 |
| Travel and Lodging | $1,478.32 |
| Honoraria | $1,200.00 |
| Education | $197.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30,451.68 | 2020-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $4,182.11 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Novartis Pharmaceuticals Corporation | $2,541.74 | 2019-2025 | |
| Pfizer INC. | $2,324.85 | 2019-2025 | |
| F. Hoffmann-La Roche Ag | $1,722.09 | 2019-2022 | |
| Celgene Corporation | $1,243.73 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $1,136.72 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Rigel Pharmaceuticals, INC. | $969.48 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Merck Sharp & Dohme LLC | $848.67 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Karyopharm Therapeutics INC. | $848.15 | 2020-2023 | Xpovio |
| Genentech USA, INC. | $831.84 | 2019-2025 | Venclexta, Lunsumio, Phesgo |
| Geron Corporation | $813.06 | 2025 | Rytelo |
| Janssen Biotech, INC. | $675.44 | 2019-2025 | Erleada, Darzalex, Talvey |
| Abbvie INC. | $647.95 | 2019-2025 | Venclexta |
| Seagen INC. | $605.38 | 2019-2023 | Padcev, Tukysa |
Show all 94 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $514.50 | 2019-2025 | |
| Amgen INC. | $505.61 | 2019-2023 | Lumakras |
| Verity Pharmaceuticals INC. | $500.00 | 2021 | |
| Emd Serono, INC. | $450.10 | 2019-2025 | Bavencio |
| Gilead Sciences, INC. | $429.36 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $413.42 | 2019-2025 | Mektovi, Lorbrena, Braftovi |
| Astellas Pharma US INC | $353.93 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2021 | |
| Eisai INC. | $332.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $323.02 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $287.86 | 2019-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $276.80 | 2019-2024 | |
| Glaxosmithkline, LLC. | $244.04 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $212.27 | 2019-2025 | Monjuvi, Zynyz |
| Puma Biotechnology, INC. | $182.37 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $171.21 | 2020-2025 | Libtayo, Lynozyfic |
| Taiho Oncology, INC. | $162.72 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $160.56 | 2020-2024 | Yonsa, Odomzo |
| Dova Pharmaceuticals | $156.54 | 2020-2021 | |
| Epizyme, INC. | $156.25 | 2020-2022 | |
| Tesaro, INC. | $147.75 | 2019 | |
| Sobi, INC | $144.39 | 2023-2025 | |
| Verastem, INC. | $137.45 | 2019 | |
| Exelixis INC. | $137.21 | 2019-2024 | Cabometyx |
| Acrotech Biopharma INC. | $135.67 | 2021-2025 | Beleodaq |
| Kite Pharma, INC. | $130.40 | 2020-2023 | |
| Beigene USA, INC. | $126.35 | 2020-2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $118.82 | 2022-2025 | Fotivda |
| Lilly USA, LLC | $112.09 | 2019-2025 | Verzenio |
| Tersera Therapeutics LLC | $95.86 | 2019-2024 | Zoladex |
| Jazz Pharmaceuticals INC. | $95.71 | 2019-2025 | Zepzelca |
| Kyowa Kirin, INC. | $87.25 | 2019-2024 | Poteligeo |
| Genmab U.S., INC. | $79.81 | 2023-2024 | Epkinly, Tivdak |
| Clovis Oncology, INC. | $73.13 | 2019-2022 | |
| US Oncology Corporate, INC. | $69.93 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $67.92 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $67.05 | 2023-2025 | |
| Immunocore Limited | $61.27 | 2025 | Kimmtrak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.58 | 2019-2021 | |
| Mylan Institutional INC. | $56.79 | 2020-2022 | |
| Morphosys, US INC. | $52.01 | 2021 | |
| Pharmaessentia USA Corporation | $49.81 | 2023-2025 | Besremi |
| Stemline Therapeutics INC. | $46.95 | 2024-2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $46.44 | 2020-2025 | Qinlock, Romvimza |
| Blue Earth Diagnostics | $45.66 | 2024-2025 | Posluma |
| Blueprint Medicines Corporation | $41.30 | 2020-2022 | |
| Avyxa Pharma, LLC | $41.15 | 2025 | |
| Apellis Pharmaceuticals, INC. | $39.56 | 2023-2024 | Empaveli |
| Celltrion USA INC. | $39.09 | 2024 | Vegzelma |
| Iovance Biotherapeutics, INC. | $38.67 | 2024-2025 | Amtagvi |
| Spectrum Pharmaceuticals INC. | $37.07 | 2023-2024 | Rolvedon |
| Mirati Therapeutics, INC. | $36.63 | 2024 | Krazati |
| Amneal Pharmaceuticals LLC | $36.21 | 2024-2025 | Pemrydi Rtu, Neulasta, Neupogen |
| Springworks Therapeutics, INC. | $35.98 | 2025 | Ogsiveo |
| Adaptive Biotechnologies Corporation | $33.85 | 2022-2024 | Clonoseq |
| Cti Biopharma Corp. | $33.46 | 2022-2023 | Vonjo |
| Foundation Medicine, INC. | $32.27 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $29.30 | 2024 | Monoferric |
| Adc Therapeutics America, INC. | $24.83 | 2025 | |
| Sumitomo Pharma America, INC. | $20.73 | 2025 | Orgovyx |
| Secura Bio, INC. | $20.50 | 2025 | Copiktra |
| Accord Healthcare, INC. | $20.17 | 2025 | |
| Medtronic, INC. | $18.14 | 2023 | Synchromedii |
| Myovant Sciences INC. | $17.24 | 2021 | |
| Tempus Ai, INC | $17.02 | 2025 | Xt Cdx |
| Beone Medicines USA, INC. | $16.94 | 2025 | Brukinsa |
| Acceleron Pharma, INC. | $16.76 | 2020 | |
| Amag Pharmaceuticals, INC. | $15.33 | 2022 | |
| Myriad Genetic Laboratories, INC. | $14.80 | 2023 | Myrisk |
| Coherus Oncology, INC. | $14.30 | 2023 | |
| Global Blood Therapeutics, INC. | $13.98 | 2021 | |
| Innate Pharma, INC | $13.97 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.91 | 2025 | Ultomiris |
| Recordati_rare_diseases_inc. | $13.88 | 2025 | Enjaymo |
| Octapharma USA, INC. | $12.79 | 2023 | Octagam Immune Globulin (Human) |
| Tolmar Pharmaceuticals, INC. | $12.71 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.67 | 2021 | |
| Aurobindo Pharma USA, INC. | $11.85 | 2020 | |
| Medtronic USA, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,536.87 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dakhil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.